News

Jacobio Pharma Unveils 2024 Results and Future Plans

Jacobio Pharma Unveils 2024 Results and Future Plans

Jacobio Pharma's Impressive 2024 Annual Results

Jacobio Pharma has shared its much-anticipated annual results for the year 2024, showcasing a revenue of RMB160 million and a substantial R&D investment of RMB330 million. With a focus on innovation, the company has achieved a considerable cash inflow of RMB320 million from various operating and financing activities. By the end of this year, Jacobio has reported a strong cash and bank balance reaching RMB1.45 billion, a strong foundation for future endeavors.

A Transformative Year for Jacobio Pharma

According to Dr. Yinxiang Wang, the Chairman and CEO of Jacobio Pharma, 2024 has been marked as a transformative year for the organization. The company has successfully submitted a New Drug Application (NDA) for its KRAS G12C inhibitor, glecirasib. Additionally, they have licensed the rights of glecirasib and the SHP2 inhibitor, sitneprotafib, to strategic partners, indicating Jacobio's evolution from early-stage research to an innovative powerhouse ready for value realization.

Exciting Road Ahead for Glecirasib

Looking towards 2025, there are high hopes for glecirasib, which is expected to receive the official marketing approval soon. This milestone is anticipated to unlock continuous cash flow, further fueling Jacobio's future pipeline of treatments.

Key Developments in Clinical Trials

Jacobio Pharma has made significant progress in developing core clinical stage products, particularly glecirasib (JAB-21822) and sitneprotafib (JAB-3312).

Focus on Non-Small Cell Lung Cancer

The company has been actively pursuing regulatory approval for glecirasib as a monotherapy for non-small cell lung cancer (NSCLC). The NDA application was submitted, and priority review designation was granted. This development positions glecirasib for potential approval in the near future.

Multi-Tumor Basket Registration Trials

A multi-tumor basket registration phase II trial for glecirasib has also commenced, targeting several types of cancer including pancreatic and gastric cancers. This trial has gained orphan drug designation from both the FDA and EMA for its indication in pancreatic cancer, marking a significant recognition of its potential.

Advancements in Other Key Projects

Jacobio is also advancing other promising candidates:

The JAB-23E73 Pan-KRAS Inhibitor

The IND applications for JAB-23E73 have been successfully approved in both key markets, allowing enrollment of the first patient, with key phases expected in 2025.

Innovative Therapies in the Pipeline

The company is pursuing a global trial for JAB-30355, a p53 Y220C activator, with approvals attained from both the FDA and CDE. Alongside, JAB-8263, a BET inhibitor, has completed crucial phases in the U.S. and China, showing promising signs in ongoing trials.

About Jacobio Pharma

Jacobio Pharma (1167.HK) is committed to advancing breakthrough therapies for patients. The company utilizes a unique induced allosteric drug discovery platform, mainly focusing on the KRAS pathway. Their strategy revolves around forging significant partnerships to catalyze innovative drug development. With R&D facilities in Asia and North America, Jacobio Pharma is a global player in cancer research, conducting clinical trials across multiple regions.

Frequently Asked Questions

What are Jacobio Pharma's notable achievements in 2024?

Jacobio Pharma achieved a revenue of RMB160 million and made significant strides in R&D, alongside successful drug application submissions.

What is the expected future for glecirasib?

Glecirasib is anticipated to receive official marketing approval soon, promising to generate ongoing revenue and investment opportunities for Jacobio's pipeline.

Which cancer treatments are in Jacobio Pharma's pipeline?

Jacobio Pharma is developing innovative treatments for NSCLC, pancreatic cancer, and other malignancies with several clinical trials underway.

Where are Jacobio Pharma's R&D centers located?

Jacobio Pharma operates R&D centers in Beijing, Shanghai, and Boston, enhancing their capabilities in drug discovery and development.

How does Jacobio Pharma envision its future?

Jacobio aims to solidify its status as a global leader in oncology research, fostering strategic partnerships to drive innovation and growth in cancer treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Dodge Roars Back to NASCAR, Revving Up Stock Gains

Updated Category News Views 0

When Dodge decides to hit the track running, they mean it. They're cranking the engines and returning to the NASCAR Cup Series after years in the shadows. This isn't just about going fast; it's about redefining speed on the stock car circuit and maybe even the market tickers. Revving an Old Engine for a New Race Let's get this out there: Dodge pulling a U-turn back into...

Continue Reading
Ultima Genomics Drives Precision Medicine Forward in Singapore

Updated Category News Views 0

A Major Milestone for Precision Medicine Ultima Genomics just nabbed a big one, folks. They're going front and center with Singapore's National Precision Medicine (NPM) Program for Phase III, marking no small feat in the ambitious world of genomics. This is more than just another feather in their cap—it's a power move in the cutthroat race for sequencing supremacy. And...

Continue Reading
Empowering Global Health: Hainan's 2026 Women's Focus

Updated Category News Views 116

Hainan Hosts a Health Heavyweight Meet Boao, Hainan, not typically on the financial radar, just played host to a global heavyweight—the 2026 International Exchange on Women and Children's Health. While the Wall Street gang's eyes are trained on market tickers, this gathering carried significant strategic weight worth monitoring. This conference attracted over 170 key...

Continue Reading
Johns Hopkins Teams with Prospect HQ for Athlete Careers

Updated Category News Views 58

Snagging a career after college isn't quite as easy as catching a football, but the folks over at Johns Hopkins University Athletics and Prospect HQ seem to think they have a playbook for it. You might raise an eyebrow hearing this, but Prospect HQ has now roped in student-athletes from over 500 colleges and universities nationwide into its talent pool. That's a hefty...

Continue Reading
Ericsson Executes Aggressive $54M Share Buyback

Updated Category News Views 62

Digging Into Ericsson's Latest Buyback Getting straight to brass tacks, the recent maneuver by Ericsson (SE0000108656)—snapping back 500,000 shares from October 26 to October 30, 2026—raised more than a few eyebrows in the financial alleys. Shelling out SEK 54.46 million in less than a week is no small potatoes, but it’s all part of a grander financial ballet...

Continue Reading
TalentNeuron Enhances Workforce Planning with New Tools

Updated Category News Views 140

A Game Changer for Workforce Strategy You ever get the feeling businesses treat workforce planning like a jigsaw puzzle, except the pieces change shape daily? Well, TalentNeuron's out here flipping the table by introducing some fancy new capabilities that'll make those pieces fit a whole lot easier. Yeah, it's about time someone thought to merge continuous workforce...

Continue Reading
New Leadership Fuels Expansion of Black Optix Tint

Updated Category News Views 90

Shifting Gears with New Leadership Black Optix Tint isn't just revamping its car-styling game; it's refueling the entire brand with the appointment of Jeff Stark as its new brand president. This guy's entry into the picture is like putting nitro in the tank of a franchise that's already got some serious road miles behind it. With over 15 years under his belt in the...

Continue Reading
YeePay's B2B Payment Innovations Target Airlines' Pain Points

Updated Category News Views 172

A New Takeoff for Airline B2B Payments Dusting off the cobwebs of traditional payment processes, YeePay has been busy at the 2026 IATA WFS & WPS, held on the glitzy floor of the Galaxy International Convention Center in Macau from October 28 to 29. They're not just chatting about travel; they're rolling out a novel way to tackle the headaches in airline B2B order...

Continue Reading
Ceva's Wireless IP Dominance Amid AI Device Surge

Updated Category News Views 104

Keeping the Wireless IP Crown Against All Odds Look, I've seen dominance play out in the markets over the years, but Ceva’s stranglehold on the wireless interface IP market is something fierce. They've got a whopping 68% market share, and folks, that’s 12 times their closest competitor. Talk about leaving the competition eating dust! For a field growing at a solid...

Continue Reading
New Study Exposes Grim Reality for Moderate Aortic Stenosis

Updated Category News Views 41

Uncovering the Stark Truth of Moderate Aortic Stenosis When you hear about heart issues, the last thing you want to think about is moderate anything. But this study out of San Diego sure throws a wrench in how we size up moderate aortic stenosis. Turns out these patients aren't just in a holding pattern—they're facing some serious storm clouds. High Stakes for...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of a $1,000 Investment in Synopsys Stock

Updated Category News Views 159

Understanding the Long-Term Value of Synopsys Stock When it comes to investing, the history and performance of a stock can tell a compelling story. For Synopsys (NASDAQ: SNPS), the narrative over the last two decades is particularly impressive. This company has not only weathered various market conditions but has also delivered an annualized return of 16.31%, eclipsing...

Continue Reading
Patria Achieves $50 Billion in Assets Under Management

Updated Category News Views 254

Patria's Impressive Third Quarter Performance Patria (NASDAQ: PAX) has recently announced its unaudited results for the third quarter, marking a notable achievement in its financial journey. The firm has achieved a milestone, with Assets Under Management (AUM) exceeding US$50 billion, significantly more than three times the AUM at the time of its initial public offering...

Continue Reading
Tech Stocks Rally Amid Mixed Investor Sentiment and Indices

Updated Category News Views 171

Market Sentiment Shifts But Caution Lingers Tuesday’s market wrapped up with the Nasdaq making a decent little rebound, gaining roughly 1%. Ain’t that a surprise? The real kicker here is the ongoing tug-of-war between fear and greed among investors—patience is wearing thin as the CNN Money Fear and Greed Index wobbles at 42.7, still stuck in the worry zone. With...

Continue Reading
Exciting Release of Find Tamagotchi on Roblox by transcosmos

Updated Category News Views 194

New Interactive Experience: Find Tamagotchi on Roblox transcosmos is thrilled to announce the launch of Find Tamagotchi on Roblox, a beloved interactive platform embraced worldwide. This innovative title is part of a broader initiative to engage fans of the iconic Tamagotchi franchise, which has been cherished by multiple generations. The adventure to find and learn about...

Continue Reading
Sesame Workshop and NewYork-Presbyterian Team Up for Health Equity

Updated Category News Views 243

Collaboration to Enhance Children's Health The partnership of Sesame Workshop and NewYork-Presbyterian aims to instill healthy habits in young children and their families. By offering free resources and engaging content, they hope to create an environment where children can thrive. Creating Joyful Learning Experiences Through this collaboration, the organizations are set...

Continue Reading